261 related articles for article (PubMed ID: 28036048)
1. Targeting Notch3 in Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Perspectives.
Giovannini C; Bolondi L; Gramantieri L
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036048
[TBL] [Abstract][Full Text] [Related]
2. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.
Giovannini C; Minguzzi M; Baglioni M; Fornari F; Giannone F; Ravaioli M; Cescon M; Chieco P; Bolondi L; Gramantieri L
Oncotarget; 2014 Nov; 5(21):10607-20. PubMed ID: 25431954
[TBL] [Abstract][Full Text] [Related]
3. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism.
Giovannini C; Gramantieri L; Chieco P; Minguzzi M; Lago F; Pianetti S; Ramazzotti E; Marcu KB; Bolondi L
J Hepatol; 2009 May; 50(5):969-79. PubMed ID: 19304334
[TBL] [Abstract][Full Text] [Related]
4. Notch3 functions as a regulator of cell self-renewal by interacting with the β-catenin pathway in hepatocellular carcinoma.
Zhang Q; Lu C; Fang T; Wang Y; Hu W; Qiao J; Liu B; Liu J; Chen N; Li M; Zhu R
Oncotarget; 2015 Feb; 6(6):3669-79. PubMed ID: 25668819
[TBL] [Abstract][Full Text] [Related]
5. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
[TBL] [Abstract][Full Text] [Related]
7. LSD1 Stimulates Cancer-Associated Fibroblasts to Drive Notch3-Dependent Self-Renewal of Liver Cancer Stem-like Cells.
Liu C; Liu L; Chen X; Cheng J; Zhang H; Zhang C; Shan J; Shen J; Qian C
Cancer Res; 2018 Feb; 78(4):938-949. PubMed ID: 29259010
[TBL] [Abstract][Full Text] [Related]
8. Notch3 intracellular domain accumulates in HepG2 cell line.
Giovannini C; Lacchini M; Gramantieri L; Chieco P; Bolondi L
Anticancer Res; 2006; 26(3A):2123-7. PubMed ID: 16827154
[TBL] [Abstract][Full Text] [Related]
9. Targeting Signalling Pathways in Hepatocellular Carcinoma.
Blagotinsek K; Rozman D
Curr Pharm Des; 2017; 23(1):170-175. PubMed ID: 27719638
[TBL] [Abstract][Full Text] [Related]
10. Targeting p53/TRAIL/caspase-8 signaling by adiponectin reverses thioacetamide-induced hepatocellular carcinoma in rats.
Nazmy EA; El-Khouly OA; Zaki MMA; Elsherbiny NM; Said E; Al-Gayyar MMH; Salem HA
Environ Toxicol Pharmacol; 2019 Nov; 72():103240. PubMed ID: 31421311
[TBL] [Abstract][Full Text] [Related]
11. Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy.
Fornaro L; Vivaldi C; Caparello C; Sacco R; Rotella V; Musettini G; Luchi S; Baldini EE; Falcone A; Masi G
Future Oncol; 2014 Feb; 10(2):285-304. PubMed ID: 24490614
[TBL] [Abstract][Full Text] [Related]
12. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
13. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of Notch3 predicts poor survival for hepatocellular carcinomas.
Hu L; Xue F; Shao M; Deng A; Wei G
Biosci Trends; 2013 Jun; 7(3):152-6. PubMed ID: 23836039
[TBL] [Abstract][Full Text] [Related]
15. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting TGF-β signaling in hepatocellular carcinoma.
Giannelli G; Mazzocca A; Fransvea E; Lahn M; Antonaci S
Biochim Biophys Acta; 2011 Apr; 1815(2):214-23. PubMed ID: 21129443
[TBL] [Abstract][Full Text] [Related]
17. Hedgehog signaling in hepatocellular carcinoma: novel therapeutic strategy targeting hedgehog signaling in HCC.
Osipo C; Miele L
Cancer Biol Ther; 2006 Feb; 5(2):238-9. PubMed ID: 16552173
[No Abstract] [Full Text] [Related]
18. Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma.
Gopalan B; Narayanan K; Ke Z; Lu T; Zhang Y; Zhuo L
Biomaterials; 2014 Aug; 35(26):7479-87. PubMed ID: 24912819
[TBL] [Abstract][Full Text] [Related]
19. Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Hao PP; Li H; Lee MJ; Wang YP; Kim JH; Yu GR; Lee SY; Leem SH; Jang KY; Kim DG
J Hepatol; 2015 Jun; 62(6):1278-86. PubMed ID: 25617504
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis.
Wang X; Bai H; Zhang X; Liu J; Cao P; Liao N; Zhang W; Wang Z; Hai C
Carcinogenesis; 2013 Jun; 34(6):1323-30. PubMed ID: 23404993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
